Navigation Links
Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
Date:6/20/2013

SAN DIEGO, June 20, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave® (naltrexone sustained release (SR) /bupropion SR) clinical data presentations taking place at the American Diabetes Association (ADA) 73rd Scientific Sessions, June 21-25, 2013.

ADA: McCormick Place Convention Center (West Building), Chicago, ILAbstract# 1056-P – "Combination Naltrexone/Bupropion Therapy Resulted in Clinically Meaningful Improvements in Weight and Quality of Life - Integrated Analysis of Four Phase 3 Trials"
Lead Author: Ronette L. Kolotkin

Abstract# 1130-P – "An Integrated Analysis of Weight Loss with Combination Naltrexone/Bupropion Therapy by BMI (Obesity) Classification"
Lead Author: Caroline M. Apovian

Abstract# 1149-P – "Early Improvement in Control of Eating Is Associated with Long-term Weight Loss - Integrated Analysis of Four Phase 3 Trials of Combination Naltrexone/Bupropion Treatment"
Lead Author: Ken Fujioka

All abstracts will be presented at General Poster Session 2, on Sunday, June 23, from 12:00 PM - 2:00 PM, in Hall F1 – Posters.

Abstract #1056-P will also be showcased in a Guided Audio Poster Tour at the Innovative Oral Agents–Innovative Discoveries session on Monday, June 24, from 1:00 PM - 2:00 PM.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
2. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
3. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
4. Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and Webcast
5. Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference
6. Orexigen Therapeutics to Present at Upcoming Investor Conferences
7. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
8. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
9. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
10. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
11. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months ... Insight is pleased to announce the appointment of three ... Tammy Wynne , Dominic Jones-Phillips and ... industry. Tammy ... team of market access writers. She has over ten ...
(Date:9/1/2017)... 2017  Bayer will present the latest research from across ... Oncology (ESMO) 2017 Congress, September 8-12 in Madrid, ... and clinical data on Bayer,s marketed portfolio and late-stage compounds ... "We value the opportunity ... research at ESMO," said Carsten Brunn , Head of ...
(Date:8/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will present at the ... in New York . John Greisch ... present at 11:05 a.m. Eastern Time. The ... A recorded replay will be available one hour after the ... About Hill-Rom Holdings, Inc. ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Swirl: A Wine Tasting Event series on Thursday, October 26, 2017. Hosted at ...
(Date:9/19/2017)... ... 19, 2017 , ... The American College of Lifestyle ... recently formed Corporate Roundtable, a group of individuals and organizations whose collective vision ... Canyon Ranch is a unique collection of lifestyle-based immersion vacation settings and programs ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... issued a rallying cry to Americans to watch for the discomforts and hidden ... young athletes to senior citizens, everyone is at risk for developing fungal infections ...
(Date:9/19/2017)... ... September 19, 2017 , ... Leonard I. Linkow, DDS, DMSC, sets ... (published by Xlibris on July of 2014). This book details the recent advances and ... approaches that benefit people who have lost all of their natural teeth . ...
(Date:9/19/2017)... Va (PRWEB) , ... September 19, 2017 , ... The ... the use of health IT to create efficiencies in healthcare information exchange and a ... the release of their latest industry white paper, entitled Barriers to Adoption of ...
Breaking Medicine News(10 mins):